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Introduction
Numerous epidemiologic studies have demonstrated the
protective effect of a full-term pregnancy before age
20 years on the risk for developing breast cancer, as com-
pared with women who have never had a full-term preg-
nancy. Rodent models can replicate the protective effect
of pregnancy against the development of carcinogen-
induced mammary cancer. Most intriguing is the ability to
prevent mammary cancers in these rodent models by
recreating the hormonal milieu of pregnancy by providing
estradiol and progesterone to achieve pregnancy levels,
either before or after the carcinogenic insult. In this issue
of Breast Cancer Research, Rajkumar and coworkers [1]
take a step further in recapitulating the protective effect of
pregnancy. They demonstrate that both natural and syn-
thetic estrogens in combination with progestins at lower
doses and with shorter durations of treatment are capable
of providing the protective effect. These studies are com-
pelling because this hormonal regimen may be applicable
to the prevention of human breast cancer. However, this
approach, despite impressive preclinical studies, may be
difficult to translate into a clinical trial.
Pregnancy and the protective effect on breast
cancer in humans and rodent models
The protective effect afforded by full-term pregnancy in
women who are 20 years old or younger, as compared
with nulliparous women, is recognized among all ethnic
groups, but the mechanism of this effect is not fully under-
stood. Rodent models have been extensively utilized to
demonstrate the role of pregnancy [2,3] and hormones
simulating pregnancy [4,5] in preventing mammary car-
cinogenesis. Actually, two separate models have been
used to demonstrate the protective effects of parity: a pre-
treatment model and a post-treatment model [6]. In the
pretreatment model the hormonal treatment is given
before the carcinogen, whereas in the post-treatment
model the carcinogen is given first, followed by the
hormone treatment. The latter is the model used by Rajkumar
and coworkers [1]. The fact that the timing of hormonal
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Abstract
At the present time, the only approved method of breast cancer prevention is use of the selective
estrogen receptor modulator (SERM) tamoxifen. Many breast cancers are driven to grow by estrogen,
and tamoxifen exploits this by blocking estrogen action at the estrogen receptor. A counter-intuitive
and controversial approach to breast cancer prevention is administration of estrogen and progestin at
an early age to achieve pregnancy levels. This approach is supported by the fact that breast cancer
incidence is halved by early (≤20 years of age) full-term pregnancy. Moreover, it has been
demonstrated in rodent models that mimicking the hormonal milieu can effectively prevent carcinogen-
induced mammary cancer. In this issue of Breast Cancer Research Rajkumar and colleagues use the
rodent model to further define the timing and type of hormonal therapy that is effective in preventing
mammary carcinogenesis. Clearly, application of this approach in humans may be difficult, but the
potential benefit is intriguing.
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treatment – before or after the carcinogenic insult – is
irrelevant to the protective effect is an important consider-
ation when devising the first clinical trial. However, the
mechanism of protection is likely to be quite different in
the two rodent models. Several hypotheses for the cellular
and molecular mechanisms underlying this protective
effect have been proposed; induction of differentiation [7],
decreased proliferation, upregulation of p53 [8], and
greater DNA repair capacity are but a few of the hypothe-
ses offered. Whatever the mechanism of protection,
based on the epidemiologic findings this protective effect
lasts throughout a woman’s lifetime and makes hormonal
mimicry of pregnancy such an attractive approach.
From rodents to teenagers: translation to the
clinic
Rodent models have been invaluable in the preclinical
evaluation of selective estrogen receptor modulators
(SERMs) and aromatase inhibitors. Indeed, had it been
known that tamoxifen caused rat liver tumors and endome-
trial cancer, it is unlikely clinical trials would have pro-
ceeded so rapidly. It is not possible to extrapolate all
possible ramifications of applying hormonal manipulation
to simulate full-term pregnancy. The difference between
the translation of SERMs into the clinic for both breast
cancer treatment and prevention, and hormonal prevention
strategies that simulate a full-term pregnancy is the age of
the target patient population. Because the hormonal treat-
ment must be administered during the teenage years, clini-
cal trials of such a treatment will probably attract more
scrutiny. The findings of Rajkumar and coworkers [1] are
likely to alleviate some of these concerns. Notably, treat-
ment with synthetic hormones such as ethynyl estradiol
plus norethindrone for only 1 week was shown to reduce
mammary cancer incidence from 75% to 25%. These syn-
thetic hormones are already used in oral contraceptive
preparations, and therefore safety issues will be less of a
concern. However, one must remember that the hormone
level that must be achieved is that of the last trimester of
pregnancy. This level is considerably higher than is found
in oral contraceptives, and this is a considerable obstacle
that must be overcome when considering treatment of
very young women. The shorter duration of treatment is
advantageous and may offset some of the drawbacks,
although the optimal duration of treatment will be difficult
to ascertain in humans.
Conclusion
The findings of Rajkumar and coworkers [1] have fascinat-
ing implications for the prevention of breast cancer in the
future. Although tamoxifen is a truly remarkable chemopre-
ventive drug, it has certain drawbacks. Tamoxifen does not
prevent the emergence of estrogen receptor negative
breast cancer [9], whereas it was recently reported that
administration of hormones to achieve pregnancy levels
does not alter the spectrum of estrogen receptor status in
resulting tumors [10]. Tamoxifen does not prevent breast
cancer in women with BRCA1 mutations [11], and unfortu-
nately it appears that an early pregnancy does not afford
protection for BRCA1 and BRCA2 mutation carriers either
[12]. Finally, tamoxifen increases the incidence of endome-
trial cancer – a problem that may be solved following publi-
cation of the results of the STAR (Study of Tamoxifen and
Raloxifene) trial, which will compare tamoxifen with the
newer SERM raloxifene [13]. It is unknown what potential
side effects may result from recapitulating the pregnancy
hormonal status in young women. Several obstacles will
have to be overcome before translation of this strategy into
the clinic. However, the potential benefit is enormous.
References
1. Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F,
Nandi S: Prevention of mammary carcinogenesis by short-
term estrogen and progestin treatments. Breast Cancer Res
2004, 6:R31-R37.
2. Sivaraman L, Stephens LC, Markaverich BM, Clark JA, Krnacik S,
Conneely OM, O’Malley BW, Medina D: Hormone-induced
refractoriness to mammary carcinogenesis in Wistar–Furth
rats. Carcinogenesis 1998, 19:1573-1581.
3. Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi
S: Hormonal prevention of breast cancer: mimicking the pro-
tective effect of pregnancy. Proc Natl Acad Sci USA 1999, 96:
2520-2525.
4. Yang J, Yoshizawa K, Nandi S, Tsubura A: Protective effects of
pregnancy and lactation against N-methyl-N-nitrosourea-
induced mammary carcinomas in female Lewis rats. Carcino-
genesis 1999, 20:623-628.
5. Russo J, Russo IH: Susceptibility of the mammary gland to car-
cinogenesis. II. Pregnancy interruption as a risk factor in
tumor incidence. Am J Pathol 1980, 100:497-512.
6. Sivaraman L, Medina D: Hormone-induced protection against
breast cancer. J Mammary Gland Biol Neoplasia 2002, 7:77-92.
7. Russo J, Russo IH: Biological and molecular bases of
mammary carcinogenesis. Lab Invest 1987, 57:112-137.
8. Medina D, Sivaraman L, Hilsenbeck SG, Conneely O, Ginger M,
Rosen J, Omalle BW: Mechanisms of hormonal prevention of
breast cancer. Ann N Y Acad Sci 2001, 952:23-35.
9. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah
M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M,
Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for pre-
vention of breast cancer: report of the National Surgical Adju-
vant Breast and Bowel Project P-1 Study. J Natl Cancer Inst
1998, 90:1371-1388.
10. Swanson SM, Christov K: Estradiol and progesterone can
prevent rat mammary cancer when administered concomi-
tantly with carcinogen but do not modify surviving tumor his-
tology, estrogen receptor alpha status or Ha-ras mutation
frequency. Anticancer Res 2003, 23:3207-3213.
11. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J,
Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher
B:  Tamoxifen and breast cancer incidence among women
with inherited mutations in BRCA1 and BRCA2: National Sur-
gical Adjuvant Breast and Bowel Project (NSABP-P1) Breast
Cancer Prevention Trial. JAMA 2001, 286:2251-2256.
12. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber
J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod
SA: Pregnancy and risk of early breast cancer in carriers of
BRCA1 and BRCA2. Lancet 1999, 354:1846-1850.
13. Wickerham DL: Tamoxifen’s impact as a preventive agent in
clinical practice and an update on the STAR trial. Recent
Results Cancer Res 2003, 163:87-95; discussion 264-266.
Correspondence
Debra A Tonetti, PhD, Department of Biopharmaceutical Sciences
(M/C 865), University of Illinois at Chicago, College of Pharmacy, 833
S. Wood Street, Room 335, Chicago, IL 60612-7231, USA. Tel: +1
312 413 1169; fax: +1 312 996 1698; e-mail: dtonetti@uic.edu